A limited series of bridgehead alkyl-, dialkyl-, and trialkyl-substituted amantadine5 was synthesized and tested for potential anti-Parkinson activity as dopamine (DA) agonists. The compounds were evaluated using a battery of three murine bioassays, including stimulation of locomotor activity, induction of circling in animals with unilateral striatal lesions, and reversal of reserpine/a-methyltyrosine induced akinesia. Apparent mechanistic differences ...
